LLY SEC Form 4 filings

Eli Lilly & Co Latest Insider Trading Activity

Our insider trading activity tracker for Eli Lilly & Co shows 11 total open-market insider transactions for LLY over the past 439 days. The most recent displayed transaction was on June 10, 2026, when Yuffa Ilya (Eli Lilly & Co EVP&Pres, LLY USA&Global Capab) reported a sale of 2,500 shares at $1,150.77 per share. This page shows up to the 10 most recent SEC Form 4 filing records on a 6-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.

Insider Trading For LLY Charted on Daily Candles. Scroll left or zoom out to load earlier candles (up to 2 years).

▲ Insider buy ▼ Insider sale
Loading daily price history…
Charting by TradingView Lightweight Charts
Ticker Filing Date Transaction Date Company Insider Title Transaction Trade Count Shares Avg. Price Total Value Position Size Change SEC Filing
10b5-1: Scheduled Form 4 Transaction LLY 2026-06-11 2026-06-10 Eli Lilly & Co Yuffa Ilya EVP&Pres, LLY USA&Global Capab Sell 1 2,500 $1,150.77 $2,876,925.00 7.74% View Filing
10b5-1: Scheduled Form 4 Transaction LLY 2025-11-13 2025-11-13 Eli Lilly & Co Zakrowski Donald A SVP, Finance, & CAO Sell 1 1,000 $1,010.50 $1,010,500.00 26.04% View Filing
10b5-1: Scheduled Form 4 Transaction LLY 2025-08-28 2025-08-28 Eli Lilly & Co Zakrowski Donald A SVP, Finance, & CAO Sell 1 1,000 $734.93 $734,930.00 20.66% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. LLY 2025-08-15 2025-08-15 Eli Lilly & Co Montarce Lucas EVP & CFO Buy 1 715 $691.79 $494,629.85 4.87% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. LLY 2025-08-14 2025-08-13 Eli Lilly & Co Alvarez Ralph Director Buy 1 758 $660.25 $500,469.50 100.00% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. LLY 2025-08-13 2025-08-13 Eli Lilly & Co Van Naarden Jacob EVP & Pres., Lilly Oncology Buy 1 1,000 $647.36 $647,360.00 4.86% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. LLY 2025-08-12 2025-08-12 Eli Lilly & Co Skovronsky Daniel EVP, CSO & Pres. LRL & LLY Imm Buy 1 1,000 $634.41 $634,410.00 0.73% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. LLY 2025-08-12 2025-08-12 Eli Lilly & Co Sulzberger Gabrielle Director Buy 1 117 $641.18 $75,018.06 4.33% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. LLY 2025-08-12 2025-08-12 Eli Lilly & Co Fyrwald J Erik Director Buy 2 1,565 $642.33 $1,005,248.61 1.06% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. LLY 2025-08-08 2025-08-08 Eli Lilly & Co Jackson Jamere Director Buy 1 200 $639.56 $127,912.00 2.13% View Filing

Pricing

Free Trial

10 trading days
$0

Explore every Premium feature before you pay.

  • Full platform access
  • 10 trading days
  • No credit card required
  • 20 years of alert history
  • Live alert directory updates
Start your free trial

Standard Monthly

Scheduled
$19.99 / month

Scheduled alerts with complete trade context.

  • Email and Telegram delivery
  • Alert intervals from every sixty minutes to once daily
  • Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
  • Highlighted cluster transactions and SEC filing links
  • Access to the alert directory hourly refreshes
Choose Standard Monthly

Premium Monthly

Recommended
$29.99 / month

Fastest alerts with ticker-level control.

  • Everything in Standard
  • Instant delivery detection-to-outbound time averages 0.89 seconds
  • Alert intervals starting from one minute
  • Real time alert directory updates
Choose Premium Monthly
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.